/PRNewswire/ SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous.
SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders and oncology, will present data on cenobamate at the American Epilepsy Society (AES) Annual Meeting, to be held December 1-5, 2023, in Orlando, Florida.
SK Life Science will present analysis of 2,131 patients taking cenobamate during Phase 2 and 3 trials showing sudden unexpected death in epilepsy (SUDEP) rate.
Cenobamate (ONTOZRY®), for the treatment of uncontrolled focal-onset seizures in adults, is now available in 5 major European countries – Germany, the UK, Italy, Spain, France – and 10 other key markets PANGYO, South Korea, Dec. 9, 2022 /PRNewswire/ SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that its European partner Angelini Pharma, an international pharmaceutical company.
SK Biopharmaceuticals Partner Angelini Pharma Launches Cenobamate in France streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.